Palkesh Jain

So like you previously guided for operational EBITDA loss of INR2 crores to INR3 crores per month. So was the guidance based on currently operational 200 beds or did it factor the commissioning of 300 beds?

Okay. And one more question. Also the new additional beds becomes operational, so should we expect the EBITDA loss to increase temporarily before improving?

So a couple of questions from my side also. So first question is like what percentage of your current exports are from U.K.? And what share do you expect the U.K. market to contribute over the medium term?

One more question. So beyond the U.K., how do you see sourcing trends evolving across Europe and the U.S.?